JP2018512150A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512150A5
JP2018512150A5 JP2017552992A JP2017552992A JP2018512150A5 JP 2018512150 A5 JP2018512150 A5 JP 2018512150A5 JP 2017552992 A JP2017552992 A JP 2017552992A JP 2017552992 A JP2017552992 A JP 2017552992A JP 2018512150 A5 JP2018512150 A5 JP 2018512150A5
Authority
JP
Japan
Prior art keywords
oncolytic virus
cancer
virus
pharmaceutical composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017552992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512150A (ja
Filing date
Publication date
Priority claimed from GBGB1505860.5A external-priority patent/GB201505860D0/en
Application filed filed Critical
Publication of JP2018512150A publication Critical patent/JP2018512150A/ja
Publication of JP2018512150A5 publication Critical patent/JP2018512150A5/ja
Pending legal-status Critical Current

Links

JP2017552992A 2015-04-07 2016-04-07 癌を治療するための治療用組成物及び使用方法 Pending JP2018512150A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1505860.5A GB201505860D0 (en) 2015-04-07 2015-04-07 Therapeutic compositions and methods of use for treating cancer
GB1505860.5 2015-04-07
PCT/GB2016/050973 WO2016162675A1 (en) 2015-04-07 2016-04-07 Therapeutic compositions and methods of use for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020199987A Division JP7066812B2 (ja) 2015-04-07 2020-12-02 癌を治療するための治療用組成物及び使用方法

Publications (2)

Publication Number Publication Date
JP2018512150A JP2018512150A (ja) 2018-05-17
JP2018512150A5 true JP2018512150A5 (https=) 2019-05-16

Family

ID=53190234

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017552992A Pending JP2018512150A (ja) 2015-04-07 2016-04-07 癌を治療するための治療用組成物及び使用方法
JP2020199987A Active JP7066812B2 (ja) 2015-04-07 2020-12-02 癌を治療するための治療用組成物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020199987A Active JP7066812B2 (ja) 2015-04-07 2020-12-02 癌を治療するための治療用組成物及び使用方法

Country Status (14)

Country Link
US (2) US20180104288A1 (https=)
EP (1) EP3280798B1 (https=)
JP (2) JP2018512150A (https=)
KR (1) KR102544032B1 (https=)
CN (1) CN107787364A (https=)
BR (1) BR112017021700A2 (https=)
CA (1) CA2981925C (https=)
ES (1) ES2743952T3 (https=)
GB (1) GB201505860D0 (https=)
HK (1) HK1251009B (https=)
IL (1) IL254842B (https=)
MX (1) MX377211B (https=)
RU (1) RU2720984C2 (https=)
WO (1) WO2016162675A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
US20220249127A1 (en) * 2019-05-14 2022-08-11 Oncolys Biopharma Inc. Method for administering oncolytic virus to tumor tissue, and device for administration
EP4087920A4 (en) * 2020-01-10 2024-02-28 The University of Hong Kong Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof
CA3199581A1 (en) * 2020-11-30 2022-06-02 Neil H. Bander Cancer immunotherapies to promote hyperacute rejection
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
WO2026068773A1 (en) * 2024-09-27 2026-04-02 Repudio Ab Immunotherapy using ggta and nap

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9810904D0 (en) 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7338932B2 (en) * 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
CN1756568A (zh) * 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)-半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
JP2008519590A (ja) * 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
US7820628B2 (en) 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
ES2733211T3 (es) * 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
KR20150093775A (ko) * 2012-12-07 2015-08-18 노쓰 캐롤라이나 스테이트 유니버시티 베타 헥소실-전이효소 및 이의 이용
CN105779397B (zh) * 2014-12-22 2019-07-19 彭霞 溶瘤异源重组新城疫病毒及其制备方法与应用

Similar Documents

Publication Publication Date Title
JP2018512150A5 (https=)
RU2017134519A (ru) Терапевтические композиции и способы применения для лечения рака
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
Everts et al. Replication-selective oncolytic viruses in the treatment of cancer
ES2987444T3 (es) Virus vaccinia recombinante y uso del mismo
JP6576326B2 (ja) 腫瘍溶解性アデノウイルス組成物
JP2017514483A5 (https=)
Wang et al. Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity
JP2007524363A (ja) 変異体水疱性口内炎ウイルスおよびそれらの使用
RU2016146664A (ru) Аденовирус, содержащий альбумин-связывающий участок
US10435672B2 (en) Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
Hastie et al. An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells
ES3014482T3 (en) Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
JP7144915B2 (ja) 腫瘍を治療するためのウイルス
Bin Liu et al. Virus, oncolytic virus and human prostate cancer
JP7737141B2 (ja) 細胞融合を誘導するワクシニアウイルス及びその利用
Gao et al. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA
Yang et al. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus
Liu et al. Oncolytic vaccinia virotherapy for endometrial cancer
Kemp et al. Characterization of a replicating expanded tropism oncolytic reovirus carrying the adenovirus E4orf4 gene
WO2020011754A1 (en) Chimeric vaccinia viruses
JP5964818B2 (ja) 乳がんのウイルス療法用薬剤
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
WO2018067165A1 (en) Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer